| Objective To explore the clinical value of high-risk human papillomavirus (HR-HPV) E6/E7 gene in screening cervical intraepithelial neoplasia (CIN2+grade) lesions. Methods From June 2016 to June 2017, 307 patients with contact vaginal bleeding or suspected cervical lesions in Gynecological Outpatient Clinic of Beijing Chuiyangliu Hospital were examined by liquid-based thin-layer cytology (TCT), HPV DNA, HPV E6/E7 mRNA, colposcopy and biopsy. The pathological results were regarded as the gold standard, and the pathological results were regarded as high-grade squamous intraepithelial lesions (HSIL), including CIN2 and CIN3, or 71 patients with cervical squamous cell carcinoma or cervical adenocarcinoma, were recorded as CIN2+. Then 236 patients with normal and low-grade squamous intraepithelial lesions (LSIL, including CIN1) as control group were recorded as CIN2-. The sensitivity and specificity of TCT, HPV DNA and HPV E6/E7 mRNA in two groups were analyzed. Results The specificity of HPV E6/E7 mRNA and HPV DNA in the diagnosis of CIN2+ was 79.66% and 19.49%, respectively, with significant difference (P<0.05). The specificity of HPV E6/E7 gene combined with TCT and HPV DNA combined with TCT in the diagnosis of CIN2+ was 82.63% and 35.17%, respectively, with significant difference (P<0.05). HPV E6/E7 and HPV DNA was 0.8420 and 0.5693 under the ROC curve of CIN2 + screening, respectively, with significant difference (P<0.05). Conclusion HPVE6/E7 mRNA is better than HPV DNA in screening CIN2+. HPVE6/E7 mRNA combined with TCT detection can improve the specificity of screening CIN2+. |
